# KEYNOTE-C93 (NCT05173987)

> Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma (MK-3475-C93/KEYNOTE-C93/GOG-3064/ENGOT-en15)

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05173987
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Merck Sharp & Dohme LLC
- Conditions: Endometrial Neoplasms
- Interventions: pembrolizumab; carboplatin; paclitaxel; docetaxel; cisplatin
- Enrollment: 280
- Primary outcome: Progression-Free Survival (PFS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR)
- Primary outcome: Overall Survival

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- YouTube: 19
- Podcasts: 17
- X threads: 4

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=keynote-c93-nct05173987

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT05173987", "email": "<work email>"}; the inbox owner confirms by the emailed link.